“…12 THR improves pain and function in patients with end-stage renal disease or post-renal transplant. 11,13 In patients without renal disease, the 30-and 90-day mortality rates are 0.24% and 0.55%, respectively, 14 and the deep infection rate, revision rate at 10 years, and dislocation rate are <1.1%, <7.5%, and <5.0%, respectively. [15][16][17] In renal transplant patients, cemented THR provides good-to-excellent functional outcomes, despite increased complication rates.…”